Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 5 | 1 | 2 | 0 | 0 |
Analyst Firms Making Recommendations1
- HC Wainwright & Co.
- Cantor Fitzgerald
- Stifel
- William Blair
- Evercore ISI Group
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Aclaris Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/14/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 946.51% | HC Wainwright & Co. | Raghuram Selvaraju | $43 → $9 | Maintains | Buy | Get Alert |
| 11/14/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | — | Cantor Fitzgerald | Louise Chen | — | Downgrade | Overweight → Neutral | Get Alert |
| 11/13/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 132.56% | Stifel | Alex Thompson | $20 → $2 | Downgrade | Buy → Hold | Get Alert |
| 11/13/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | — | William Blair | Tim Lugo | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/09/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 4318.6% | Cantor Fitzgerald | Louise Chen | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 10/04/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 4900% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 2458.14% | Evercore ISI Group | Gavin Clark-Gartner | → $22 | Initiates | → Outperform | Get Alert |
| 09/19/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 4318.6% | Cantor Fitzgerald | Louise Chen | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 09/19/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 4900% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 2225.58% | Stifel | Alex Thompson | $16 → $20 | Maintains | Buy | Get Alert |
| 08/08/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 4900% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 4900% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 2341.86% | Goldman Sachs | Corinne Jenkins | $25 → $21 | Maintains | Buy | Get Alert |
| 03/07/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 3272.09% | BTIG | Julian Harrison | $32 → $29 | Maintains | Buy | Get Alert |
| 03/07/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 4900% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $43 | Maintains | Buy | Get Alert |
| 02/24/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 5713.95% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | → Buy | Get Alert |
| 02/07/2023 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 4318.6% | Cantor Fitzgerald | Louise Chen | → $38 | Reiterates | → Overweight | Get Alert |
| 12/14/2022 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 3272.09% | Stifel | Alex Thompson | → $29 | Initiates | → Buy | Get Alert |
| 12/01/2022 | ACRS | Buy Now | Aclaris Therapeutics | $0.86 | 2806.98% | Goldman Sachs | Corinne Jenkins | → $25 | Initiates | → Buy | Get Alert |
What is the target price for Aclaris Therapeutics (ACRS)?
The latest price target for Aclaris Therapeutics (NASDAQ: ACRS) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $9.00 expecting ACRS to rise to within 12 months (a possible 946.51% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aclaris Therapeutics (ACRS)?
The latest analyst rating for Aclaris Therapeutics (NASDAQ: ACRS) was provided by HC Wainwright & Co., and Aclaris Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Aclaris Therapeutics (ACRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Aclaris Therapeutics (ACRS) correct?
While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a maintained with a price target of $43.00 to $9.00. The current price Aclaris Therapeutics (ACRS) is trading at is $0.86, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.